Reviews Imogam Rabies


No reviews yet.

Imogam Rabies Drug Description
Imogam® Rabies – HT
Rabies Immune Globulin (human), USP

DRUG DESCRIPTION



What are the possible side effects of rabies vaccine (Imovax Rabies (obsolete), Imovax Rabies I.D. (obsolete), RabAvert (obsolete), Rabies Vaccine (obsolete))?

Getting rabies disease is much riskier than getting rabies vaccine. However, a vaccine, like any medicine, is capable of causing serious problems, such as severe allergic reactions. The risk of rabies vaccine causing serious harm, or death, is extremely small.
Seek emergency medical attention or contact your doctor immediately if any of the following rare but serious side effects from rabies vaccine are...
Read All Potential Side Effects for Imogam Rabies »




Rabies Immune Globulin (Human) USP, Imogam® Rabies – HT, is a sterile solution of antirabies immunoglobulin (10-18% protein) for intramuscular administration. It is prepared by cold alcohol fractionation from pooled venous plasma of individuals immunized with Rabies Vaccine prepared from human diploid cells (HDCV). The product is stabilized with 0. 3 M glycine. The globulin solution has a pH of 6. 8 ± 0. 4 adjusted with sodium hydroxide or hydrochloric acid. No preservatives are added. Imogam® Rabies – HT is a colorless to light opalescent liquid.
A heat-treatment process step (58° to 60°C, 10 hours) to inactivate viruses has been added to further reduce any risk of blood-borne viral transmission. The inactivation and removal of model and laboratory strains of enveloped and non-enveloped viruses during the manufacturing and heat treatment processes for Imogam® Rabies – HT has been validated by spiking experiments. Human immunodeficiency virus, type 1 (HIV-1) and type 2 (HIV-2) were selected as relevant viruses for plasma derived products. Bovine viral diarrhea virus and Sindbis virus were chosen to model hepatitis C virus. Porcine pseudorabies virus was selected to model hepatitis B virus and herpes virus. Avian reovirus was used to model non-enveloped RNA viruses and for its relative resistance to inactivation by chemical and physical methods. Finally, porcine parvovirus was selected to model human parvovirus B19 and its notable resistance to inactivation by heat treatment.
Removal and/or inactivation of the studied enveloped and non-enveloped model viruses was demonstrated at the precipitation III stage of manufacturing. In addition, inactivation was demonstrated to occur during the 10-hour (58° to 60°C) heat treatment process for the studied enveloped and non-enveloped viruses.
The product is standardized against the United States (US) Standard Rabies
Immune Globulin. The US unit of potency is equivalent to the International Unit
(IU) for rabies antibody. The minimal potency is 150 IU/mL. Last reviewed on RxList: 10/23/2008




Imogam Rabies Drug Description
Imogam® Rabies – HT
Rabies Immune Globulin (human), USP

DRUG DESCRIPTION



What are the possible side effects of rabies vaccine (Imovax Rabies (obsolete), Imovax Rabies I.D. (obsolete), RabAvert (obsolete), Rabies Vaccine (obsolete))?

Getting rabies disease is much riskier than getting rabies vaccine. However, a vaccine, like any medicine, is capable of causing serious problems, such as severe allergic reactions. The risk of rabies vaccine causing serious harm, or death, is extremely small.
Seek emergency medical attention or contact your doctor immediately if any of the following rare but serious side effects from rabies vaccine are...
Read All Potential Side Effects for Imogam Rabies »




Rabies Immune Globulin (Human) USP, Imogam® Rabies – HT, is a sterile solution of antirabies immunoglobulin (10-18% protein) for intramuscular administration. It is prepared by cold alcohol fractionation from pooled venous plasma of individuals immunized with Rabies Vaccine prepared from human diploid cells (HDCV). The product is stabilized with 0. 3 M glycine. The globulin solution has a pH of 6. 8 ± 0. 4 adjusted with sodium hydroxide or hydrochloric acid. No preservatives are added. Imogam® Rabies – HT is a colorless to light opalescent liquid.
A heat-treatment process step (58° to 60°C, 10 hours) to inactivate viruses has been added to further reduce any risk of blood-borne viral transmission. The inactivation and removal of model and laboratory strains of enveloped and non-enveloped viruses during the manufacturing and heat treatment processes for Imogam® Rabies – HT has been validated by spiking experiments. Human immunodeficiency virus, type 1 (HIV-1) and type 2 (HIV-2) were selected as relevant viruses for plasma derived products. Bovine viral diarrhea virus and Sindbis virus were chosen to model hepatitis C virus. Porcine pseudorabies virus was selected to model hepatitis B virus and herpes virus. Avian reovirus was used to model non-enveloped RNA viruses and for its relative resistance to inactivation by chemical and physical methods. Finally, porcine parvovirus was selected to model human parvovirus B19 and its notable resistance to inactivation by heat treatment.
Removal and/or inactivation of the studied enveloped and non-enveloped model viruses was demonstrated at the precipitation III stage of manufacturing. In addition, inactivation was demonstrated to occur during the 10-hour (58° to 60°C) heat treatment process for the studied enveloped and non-enveloped viruses.
The product is standardized against the United States (US) Standard Rabies
Immune Globulin. The US unit of potency is equivalent to the International Unit
(IU) for rabies antibody. The minimal potency is 150 IU/mL. Last reviewed on RxList: 10/23/2008




Imogam Rabies Drug Description
Imogam® Rabies – HT
Rabies Immune Globulin (human), USP

DRUG DESCRIPTION



What are the possible side effects of rabies vaccine (Imovax Rabies (obsolete), Imovax Rabies I.D. (obsolete), RabAvert (obsolete), Rabies Vaccine (obsolete))?

Getting rabies disease is much riskier than getting rabies vaccine. However, a vaccine, like any medicine, is capable of causing serious problems, such as severe allergic reactions. The risk of rabies vaccine causing serious harm, or death, is extremely small.
Seek emergency medical attention or contact your doctor immediately if any of the following rare but serious side effects from rabies vaccine are...
Read All Potential Side Effects for Imogam Rabies »




Rabies Immune Globulin (Human) USP, Imogam® Rabies – HT, is a sterile solution of antirabies immunoglobulin (10-18% protein) for intramuscular administration. It is prepared by cold alcohol fractionation from pooled venous plasma of individuals immunized with Rabies Vaccine prepared from human diploid cells (HDCV). The product is stabilized with 0. 3 M glycine. The globulin solution has a pH of 6. 8 ± 0. 4 adjusted with sodium hydroxide or hydrochloric acid. No preservatives are added. Imogam® Rabies – HT is a colorless to light opalescent liquid.
A heat-treatment process step (58° to 60°C, 10 hours) to inactivate viruses has been added to further reduce any risk of blood-borne viral transmission. The inactivation and removal of model and laboratory strains of enveloped and non-enveloped viruses during the manufacturing and heat treatment processes for Imogam® Rabies – HT has been validated by spiking experiments. Human immunodeficiency virus, type 1 (HIV-1) and type 2 (HIV-2) were selected as relevant viruses for plasma derived products. Bovine viral diarrhea virus and Sindbis virus were chosen to model hepatitis C virus. Porcine pseudorabies virus was selected to model hepatitis B virus and herpes virus. Avian reovirus was used to model non-enveloped RNA viruses and for its relative resistance to inactivation by chemical and physical methods. Finally, porcine parvovirus was selected to model human parvovirus B19 and its notable resistance to inactivation by heat treatment.
Removal and/or inactivation of the studied enveloped and non-enveloped model viruses was demonstrated at the precipitation III stage of manufacturing. In addition, inactivation was demonstrated to occur during the 10-hour (58° to 60°C) heat treatment process for the studied enveloped and non-enveloped viruses.
The product is standardized against the United States (US) Standard Rabies
Immune Globulin. The US unit of potency is equivalent to the International Unit
(IU) for rabies antibody. The minimal potency is 150 IU/mL. Last reviewed on RxList: 10/23/2008




Imogam Rabies Drug Description
Imogam® Rabies – HT
Rabies Immune Globulin (human), USP

DRUG DESCRIPTION



What are the possible side effects of rabies vaccine (Imovax Rabies (obsolete), Imovax Rabies I.D. (obsolete), RabAvert (obsolete), Rabies Vaccine (obsolete))?

Getting rabies disease is much riskier than getting rabies vaccine. However, a vaccine, like any medicine, is capable of causing serious problems, such as severe allergic reactions. The risk of rabies vaccine causing serious harm, or death, is extremely small.
Seek emergency medical attention or contact your doctor immediately if any of the following rare but serious side effects from rabies vaccine are...
Read All Potential Side Effects for Imogam Rabies »




Rabies Immune Globulin (Human) USP, Imogam® Rabies – HT, is a sterile solution of antirabies immunoglobulin (10-18% protein) for intramuscular administration. It is prepared by cold alcohol fractionation from pooled venous plasma of individuals immunized with Rabies Vaccine prepared from human diploid cells (HDCV). The product is stabilized with 0. 3 M glycine. The globulin solution has a pH of 6. 8 ± 0. 4 adjusted with sodium hydroxide or hydrochloric acid. No preservatives are added. Imogam® Rabies – HT is a colorless to light opalescent liquid.
A heat-treatment process step (58° to 60°C, 10 hours) to inactivate viruses has been added to further reduce any risk of blood-borne viral transmission. The inactivation and removal of model and laboratory strains of enveloped and non-enveloped viruses during the manufacturing and heat treatment processes for Imogam® Rabies – HT has been validated by spiking experiments. Human immunodeficiency virus, type 1 (HIV-1) and type 2 (HIV-2) were selected as relevant viruses for plasma derived products. Bovine viral diarrhea virus and Sindbis virus were chosen to model hepatitis C virus. Porcine pseudorabies virus was selected to model hepatitis B virus and herpes virus. Avian reovirus was used to model non-enveloped RNA viruses and for its relative resistance to inactivation by chemical and physical methods. Finally, porcine parvovirus was selected to model human parvovirus B19 and its notable resistance to inactivation by heat treatment.
Removal and/or inactivation of the studied enveloped and non-enveloped model viruses was demonstrated at the precipitation III stage of manufacturing. In addition, inactivation was demonstrated to occur during the 10-hour (58° to 60°C) heat treatment process for the studied enveloped and non-enveloped viruses.
The product is standardized against the United States (US) Standard Rabies
Immune Globulin. The US unit of potency is equivalent to the International Unit
(IU) for rabies antibody. The minimal potency is 150 IU/mL. Last reviewed on RxList: 10/23/2008




Imogam Rabies Drug Description
Imogam® Rabies – HT
Rabies Immune Globulin (human), USP

DRUG DESCRIPTION



What are the possible side effects of rabies vaccine (Imovax Rabies (obsolete), Imovax Rabies I.D. (obsolete), RabAvert (obsolete), Rabies Vaccine (obsolete))?

Getting rabies disease is much riskier than getting rabies vaccine. However, a vaccine, like any medicine, is capable of causing serious problems, such as severe allergic reactions. The risk of rabies vaccine causing serious harm, or death, is extremely small.
Seek emergency medical attention or contact your doctor immediately if any of the following rare but serious side effects from rabies vaccine are...
Read All Potential Side Effects for Imogam Rabies »




Rabies Immune Globulin (Human) USP, Imogam® Rabies – HT, is a sterile solution of antirabies immunoglobulin (10-18% protein) for intramuscular administration. It is prepared by cold alcohol fractionation from pooled venous plasma of individuals immunized with Rabies Vaccine prepared from human diploid cells (HDCV). The product is stabilized with 0. 3 M glycine. The globulin solution has a pH of 6. 8 ± 0. 4 adjusted with sodium hydroxide or hydrochloric acid. No preservatives are added. Imogam® Rabies – HT is a colorless to light opalescent liquid.
A heat-treatment process step (58° to 60°C, 10 hours) to inactivate viruses has been added to further reduce any risk of blood-borne viral transmission. The inactivation and removal of model and laboratory strains of enveloped and non-enveloped viruses during the manufacturing and heat treatment processes for Imogam® Rabies – HT has been validated by spiking experiments. Human immunodeficiency virus, type 1 (HIV-1) and type 2 (HIV-2) were selected as relevant viruses for plasma derived products. Bovine viral diarrhea virus and Sindbis virus were chosen to model hepatitis C virus. Porcine pseudorabies virus was selected to model hepatitis B virus and herpes virus. Avian reovirus was used to model non-enveloped RNA viruses and for its relative resistance to inactivation by chemical and physical methods. Finally, porcine parvovirus was selected to model human parvovirus B19 and its notable resistance to inactivation by heat treatment.
Removal and/or inactivation of the studied enveloped and non-enveloped model viruses was demonstrated at the precipitation III stage of manufacturing. In addition, inactivation was demonstrated to occur during the 10-hour (58° to 60°C) heat treatment process for the studied enveloped and non-enveloped viruses.
The product is standardized against the United States (US) Standard Rabies
Immune Globulin. The US unit of potency is equivalent to the International Unit
(IU) for rabies antibody. The minimal potency is 150 IU/mL. Last reviewed on RxList: 10/23/2008





Other reviews about Imogam Rabies on wordpress

Lack of med but no lack of issues
  by welovemactan
http://www.sunstar.com.ph/static/ceb/2003/05/07/feat/lack.of.med.but.no.lack.of.issues..html Wednesday, May 07, 2003 By Oscar C. Pineda "Last Nov. 14, Sun.Star reported that the City Government bought medicine at prices double or triple the prices canvassed two months before. […]



Other reviews about Imogam Rabies on web:

Learn about the prescription medication Imogam Rabies (Rabies Immune Globulin (Human)), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Imogam Rabies (Rabies Immune Globulin (Human)) Drug Information ...


IMOGAM® RABIES PASTEURIZED : Connaught : Rabies Immune Globulin, Pasteurized (Human) Immunotherapeutic Agent - Passive Immunization Action And Clinical Pharmacology: Infection with ... RxMed: Pharmaceutical Information - IMOGAM


sanofi pasteur Product Monograph 194 - IMOGAM ® Rabies Pasteurized Page 2 of 18 Product Monograph IMOGAM ® Rabies Pasteurized [Rabies Immune Globulin, Pasteurized (Human)] ... PRODUCT MONOGRAPH


Resources for You. Untitled Letters Regarding Advertising & Promotional Labeling for Approved Biologics -- Rabies Immune Globulin (Human), Imogam Rabies-HT and Rabies ...


Side effects to the IMOGAM Rabies-HT immune globulin include injection site tenderness, pain, and muscle soreness or stiffness. Other side effects may occur. Vaccines and the Infectious Diseases They Prevent


Imogam Rabies-HT Drug Information from Drugs.com. Includes Imogam Rabies-HT side effects, interactions and indications. Imogam Rabies-HT Drug Information, Professional


AHFS Category: 80:04 Rabies Immune Globulin (Human) USP, Heat Treated Imogam® Rabies - HT FOR INTRAMUSCULAR USE ONLY DESCRIPTION Rabies Immune Globulin (Human) USP, Heat Treated, Imogam ... Rabies Immune Globulin (Human) USP, Heat Treated


Find patient medical information for Imogam Rabies IM on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings. Imogam Rabies IM : Uses, Side Effects, Interactions, Pictures ...


If possible, the full dose of IMOGAM Rabies–HT Immune Globulin should be infiltrated around the wound(s); any remaining volume should be given as an intramuscular injection at a ... Vaccines and the Infectious Diseases They Prevent


Imogam Rabies-HT patient information. Detailed drug information for the consumer, includes dosage, Imogam Rabies-HT side effects and more. Imogam Rabies-HT consumer information from Drugs.com





Featured Reviews

Reviews Cetacaine

Cetacaine Drug Description Cetacaine Topical Anesthetic(Cetylite)

DRUG DESCRIPTION ACTIVE INGREDIENTS Benzocaine                      &...

Read More  |  Review This
Reviews Hemin

Panhematin Drug Description Panhematin® (hemin) for Injection PANHEMATIN (hemin for injection) should only be used by physicians experienced in the management of porphyrias in hospitals where the recommended clinical and laboratory...
Read More  |  Review This
Reviews Chlorthalidone

Thalitone Drug Description Thalitone® (chlorthalidone) Tablets, USP DRUG DESCRIPTION What are the possible side effects of chlorthalidone (Thalitone)? Get emergency medical help if you have any of these signs of an allergic...
Read More  |  Review This
Reviews Viracept

Viracept Drug Description VIRACEPT® (nelfinavir mesylate) Tablets and Oral Powder DRUG DESCRIPTION What are the possible side effects of nelfinavir (Viracept)? Get emergency medical help if you have any of these signs of an...
Read More  |  Review This
Reviews Phenylephrine, Pyrilamine Maleate, and Dextromethorphan HBr

Deconsal DM Drug Description Deconsal® DM (phenylephrine, pyrilamine maleate, and dextromethorphan HBr) Tannate Chewable Tablets DRUG DESCRIPTION Deconsal® DM Tannate Chewable Tablets are an antihistamine/nasal decongestant/antitussive...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....